Fortress Biotech, Inc.
Qualité des données : 100%
2,41 €
▼
0,02 €
(-0,62%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-2,07%
Croissance
Revenue Growth (5Y)
-2,07%
En dessous de la moyenne du secteur (1,72%)
Revenue (1Y)9,69%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
13,66%
Au-dessus de la moyenne du secteur (-54,47%)
ROIC-48,30%
Net Margin10,77%
Op. Margin-111,00%
Sécurité
Debt / Equity
0,86
Au-dessus de la moyenne du secteur (0,30)
Current Ratio2,19
Interest Coverage-6,95
Valorisation
PE (TTM|NTM|2027)
11,27 | 4,65 | 4,73
Au-dessus de la moyenne du secteur (-1,50)
P/B Ratio1,37
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue declined -2,07% annually over 5 years
ROE of 13,66% — decent returns on equity
Negative free cash flow of -65,78 M
P/E of 11,27 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 11,76%
Price History
Tendances Financières
Objectif de Cours des Analystes
2 analystes
Buy
+347.0%
upside to target
Actuel
2,41 €
Consensus Target
10,75 €
4,50 €
Bas
17,00 €
Haut
Prévisions
P/E Prévisionnel
4,65
BPA Prévisionnel
0,51 €
CA Est.
135,31 M
Surprises de Résultats
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -0,22 €
·
Rev Est: 16,34 M
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -0,48 € | -0,51 € | 0,11 € | -0,21 € | — | — |
| Estimate | -0,44 € | -0,31 € | -0,63 € | 0,11 € | -0,22 € | -0,19 € |
| Surprise | -9,09% | -65,29% | +117,60% | -290,91% | — | — |
Growth
Rev 5Y: -2,07% · Earnings 1Y: N/A
Growth
Rev 5Y: -2,07% · Earnings 1Y: N/A| Revenue Growth (1Y) | 9,69% | Revenue Growth (3Y) | -13,48% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -2,07% | Earnings Growth (5Y) | N/A |
Profitability
ROE: 13,66% · Net Margin: 10,77%
Profitability
ROE: 13,66% · Net Margin: 10,77%| Revenue (TTM) | 63,26 M | Net Income (TTM) | 6,82 M |
| ROE | 13,66% | ROA | 3,99% |
| Gross Margin | N/A | Operating Margin | -111,00% |
| Net Margin | 10,77% | Free Cash Flow (TTM) | -65,78 M |
| ROIC | -48,30% | FCF Growth (3Y) | N/A |
Safety
D/E: 0,86 · Current: 2,19
Safety
D/E: 0,86 · Current: 2,19| Debt / Equity | 0,86 | Current Ratio | 2,19 |
| Interest Coverage | -6,95 | Asset Turnover | 0,37 |
| Working Capital | 64,44 M | Tangible Book Value | 27,19 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: 11,27 · EV/EBITDA: N/A
Valuation
P/E: 11,27 · EV/EBITDA: N/A| P/E Ratio | 11,27 | Forward P/E | 4,65 |
| P/B Ratio | 1,37 | P/S Ratio | 1,21 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 0,57 | Fwd Earnings Yield | 21,51% |
| FCF Yield | -85,64% | ||
| Market Cap | 76,80 M | Enterprise Value | 38,36 M |
Per Share
EPS: -0,07 · FCF/Share: -2,04
Per Share
EPS: -0,07 · FCF/Share: -2,04| EPS (Diluted TTM) | -0,07 | Revenue / Share | 1,96 |
| FCF / Share | -2,04 | OCF / Share | -2,04 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: -965,18% · CapEx/Rev: N/A
Efficiency
FCF Conv: -965,18% · CapEx/Rev: N/A| CapEx / Revenue | N/A | FCF Conversion | -965,18% |
| SBC-Adj. FCF | -98,63 M | Growth Momentum | 11,76 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 63,26 M | 57,68 M | 84,51 M | 75,74 M | 68,79 M |
| Net Income | 6,82 M | -46,00 M | -60,64 M | -86,58 M | -64,70 M |
| EPS (Diluted) | -0,07 | -2,69 | -8,47 | -0,97 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -70,22 M | -110,38 M | -142,34 M | -203,56 M | -188,54 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | 106,07 M | 134,88 M | 128,87 M |
| SG&A Expenses | 96,40 M | 87,73 M | 94,12 M | 113,66 M | 86,84 M |
| D&A | — | — | — | — | — |
| Interest Expense | 10,11 M | 13,53 M | 15,32 M | 12,48 M | 15,31 M |
| Income Tax | -620 000,0 | 312 000,0 | 521 000,0 | 449 000,0 | 473 000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 185,55 M | 144,22 M | 167,53 M | 294,30 M | 396,50 M |
| Total Liabilities | 123,37 M | 145,87 M | 165,94 M | 244,28 M | 170,63 M |
| Shareholders' Equity | 49,87 M | 22,74 M | 22,54 M | 41,72 M | 108,67 M |
| Total Debt | 52,42 M | 57,96 M | 60,86 M | 91,73 M | 42,94 M |
| Cash & Equivalents | 79,38 M | 57,26 M | 80,93 M | 178,27 M | 305,74 M |
| Current Assets | 123,84 M | 90,37 M | 117,02 M | 230,43 M | 346,46 M |
| Current Liabilities | 49,74 M | 71,40 M | 84,91 M | 127,72 M | 101,04 M |
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1605 pairs)
Par rapport à des entreprises similaires dans Manufacturing
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1605 pairs) Par rapport à des entreprises similaires dans Manufacturing| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 11,3 | -1,5 |
| P/B | 1,4 | 1,6 |
| ROE % | 13,7 | -54,5 |
| Net Margin % | 10,8 | -41,5 |
| Rev Growth 5Y % | -2,1 | 1,7 |
| D/E | 0,9 | 0,3 |
{"event":"ticker_viewed","properties":{"ticker":"FBIO","listing_kind":"stock","pathname":"/stocks/fbio","exchange":"NASDAQ","country":"US"}}